EMERGING MARKETS-Stocks extend gains, Hungary outperforms on reopening plans [Reuters]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Reuters
EMERGING MARKETS-Stocks extend gains, Hungary outperforms on reopening plans * Hungarian forint, stocks lead gains * South African assets under pressure after S&P downgrade * Russia’s rouble preferred in high yielding EMFX- Analyst By Ambar Warrick April 30 (Reuters) - Emerging market stocks rose on Thursday, extending recent gains as investors hoped for an effective COVID-19 treatment, while several nations looked set to emerge from lockdowns. Hungarian stocks were among the top gainers, adding more than 2%, after the country lifted restrictions outside its capital. The forint rose 0.4% to the euro. Prime Minister Viktor Orban had earlier said that the country’s economy would recover swiftly after emerging from a lockdown. Broader risk appetite was bolstered by drugmaker Gilead Sciences Inc announcing that its drug remdesivir was showing promise as an effective COVID-19 treatment, helping markets shrug off dismal U.S. GDP data and words of warning from Federal Reserve Chair Jerome Po
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences: Why I'm Tempted To Sell Ahead Of Q1 Earnings - But Won't [Seeking Alpha]Seeking Alpha
- Arcus halts Gilead-partnered late-stage trial for lung cancer drug [Seeking Alpha]Seeking Alpha
- Citi Raises Gilead (GILD) Price Target Ahead of Q1 Biopharma Preview [Yahoo! Finance]Yahoo! Finance
- Jim Cramer on Gilead Sciences: “I'd Hold On to It” [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences (GILD) had its price target raised by The Goldman Sachs Group, Inc. from $125.00 to $130.00. They now have a "neutral" rating on the stock.MarketBeat
GILD
Earnings
- 2/10/26 - Beat
GILD
Sec Filings
- 4/16/26 - Form 4
- 4/16/26 - Form 4
- 4/15/26 - Form 144
- GILD's page on the SEC website